Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Talimogene laherparepvec tested in combination with CTLA-4 or PD-1 in advanced-stage melanoma patients resulted in increased treatment response rates compared to immune checkpoint inhibitors alone.
“The virus has been tested in recent clinical trials in combination with either CTLA-4 or PD-1 in advanced-stage melanoma patients, resulting in increased treatment response rates compared to the immune checkpoint inhibitors alone (123, 124).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · see citing works
“…study of talimogene laherparepvec combined with the checkpoint inhibitor ipilimumab, which blocks the cytotoxic T-cell−associated antigen 4 (CTLA-4) (Chesney et al., 2016; Puzanov et al., 2016), and was confirmed in a phase 2 randomized trial comparing the same combination with ipilimumab alone…”
InfluentialSelf-citationAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
“The virus has been tested in recent clinical trials in combination with either CTLA-4 or PD-1 in advanced-stage melanoma patients, resulting in increased treatment response rates compared to the immune checkpoint inhibitors alone (123, 124).”
BackgroundOncolytic Virotherapy: A Contest between Apples and Oranges
Russell, S. J., & Peng, K.-W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.026 · Cited by 117 · see citing works
Biomaterial‐Based In Situ Cancer Vaccines
Yang, B., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202210452 · Cited by 99 · see citing works
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Pol, J. G., Lévesque, S., Workenhe, S. T., Gujar, S. A., Bœuf, F. L., Clements, D. R., Fahrner, J., Fend, L., Bell, J. C., Mossman, K. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1503032 · Cited by 77 · see citing works
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Dummer, R., Höeller, C., Grüter, I. P., & Michielin, O. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1967-1 · Cited by 68 · see citing works
“An interim analysis from this study was recently performed [54].”
BackgroundMethodA Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model
Hamilton, J. R., Vijayakumar, G., & Palese, P. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.025 · Cited by 60 · see citing works
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot, J., & Stein, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3920 · Cited by 59 · see citing works
Kaufman, H. L., Schwartz, L. H., William, W. N., Sznol, M., Fahrbach, K. R., Xu, Y., Masson, E., & Vergara-Silva, A. L. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2738-x · Cited by 37 · see citing works
Self-citationSIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis
Muscolini, M., Castiello, L., Palermo, E., Zevini, A., Ferrari, M., Olagnier, D. P., & Hiscott, J. B. (2019) · Journal of Virology · doi:10.1128/jvi.00626-19 · Cited by 26 · see citing works
“The therapeutic potential of oncolytic viruses (OVs) has been highlighted by the approval of the oncolytic recombinant herpesvirus talimogene laherparepvec (T-VEC) for the treatment of inoperable malignant melanoma (3) as well as by recent preclinical trials combining OV therapies with the use of immune checkpoint inh…”
BackgroundFuture perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Ascierto, P. A., Agarwala, S. S., Ciliberto, G., Demaria, S., Dummer, R., Duong, C. P. M., Ferrone, S., Formenti, S. C., Garbe, C., Halaban, R., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1341-2 · Cited by 21 · see citing works
“ORR was higher for T-VEC in combination with ipilimumab vs ipilimumab alone [83].”
BackgroundSelf-citationTherapeutic oncolytic viruses: clinical advances and future directions
Warner, S. G., O’Leary, M. P., & Fong, Y. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000388 · Cited by 19 · see citing works
Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral, T. M. S., Meraz-Torres, F., & Garbe, C. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1378640 · Cited by 14 · see citing works
“Nevertheless, these results need further confirmation from the ongoing trials, namely the phase II part of the NCT01740297 trial evaluating ipilimumab plus T-VEC versus ipilimumab alone, and the phase III part of the MASTERKEY trial (NCT02263508) evaluating pembrolizumab plus T-VEC versus pembrolizumab alone.”
BackgroundResultInfluentialInnovative Therapy, Monoclonal Antibodies and Beyond
Nicola, M. D., Apétoh, L., Bellone, M., Colombo, M. P., Dotti, G., Ferrone, S., Muscolini, M., Hiscott, J. B., Anichini, A., Pupa, S. M., et al. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.10.002 · Cited by 8 · see citing works
- Authors
- Chesney, J., Collichio, F., Andtbacka, R. H. I., Puzanov, I., Glaspy, J., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., Chen, L., Kim, J. J., & Kaufman, H. L.
- Affiliations
- University of Louisville (US)
- University of North Carolina at Chapel Hill (US)
- Huntsman Cancer Institute (US)
- Vanderbilt University (US)
- University of California, Los Angeles (US)
- University of Iowa (US)
- Angeles Clinic and Research Institute (US)
- University of Arizona Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Amgen (United States) (US)
- Rutgers Cancer Institute (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 27
- Pages
- vi380
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2588209419
- Cited by
- 15
- References
- 0
- Citations by year
- 2023: 1 · 2021: 1 · 2019: 2 · 2018: 4 · 2017: 7
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- talimogene laherparepvec, ipilimumab, melanoma, oncolytic virotherapy, anti-CTLA-4 antibody, combination immunotherapy, GM-CSF, antitumor immunity, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
